Novartis AG
(NYSE: NVS)
|
5:00 PM UTC, 07/03/24 | |||
---|---|---|---|---|
Last: $106.78 | Change: +0.34 | %Change: +0.32% | Volume: 516,074 |
Open: | $ 106.57 | Volume: | 516,074 | |
---|---|---|---|---|
High: | $ 107.03 | Yield(%) | 3.01 | |
Low: | $ 106.51 | P/E Ratio (ttm): | 14.35 | |
Dividend ($): | 3.20 | Market Cap ($): | 208.25B | |
EPS ($) | 7.42 | Shares Out: | 1.96B |
% Price Change (last 4 weeks): | 1.45 |
---|---|
% Price Change (last 13 weeks): | 12.74 |
% Price Change (last 26 weeks): | 5.39 |
% Price Change (last 52 weeks): | 13.88 |
% Price Change (year to date): | 5.42 |
Return on Equity (%): | 16.16 |
---|---|
Return on Assets (%): | 7.60 |
Return on Invested Capital (%): | 12.95 |
Gross Profit Margin (%): | 72.33 |
---|---|
Net Profit Margin (%): | 18.86 |
Operating Profit Margin (%): | 26.12 |
|
|
50-day Moving Average: | $102.37 |
---|---|
200-day Moving Average: | $99.63 |
Avg. Daily Vol. (last 50 days): | 1,430,227 |
Avg. Daily Vol. (last 200 days): | 1,504,463 |
52-wk high: | $108.78 |
52-wk low: | $89.00 |
Bid: | $105.00 |
Ask: | $108.00 |
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
|
Earnings (1year) ($): | 7.42 |
---|---|
Annual Dividend ($): | 3.20 |
Current P/E Ratio (ttm): | 14.35 |
Book Value ($): | 22.83 |
Cash Flow ($): | 11.31 |
Price/Earnings (x): | 14.35 |
---|---|
Price/Sales (x): | 4.65 |
Price/Book (x): | 4.42 |
Price/Cash Flow (x): | 14.61 |
Quick Ratio (x): | 0.93 |
---|---|
Current Ratio (x): | 1.16 |
LT Debt/Equity (x): | 42.93 |
Total Debt/Equity (x): | 56.46 |